JP2018196385A5 - - Google Patents

Download PDF

Info

Publication number
JP2018196385A5
JP2018196385A5 JP2018145578A JP2018145578A JP2018196385A5 JP 2018196385 A5 JP2018196385 A5 JP 2018196385A5 JP 2018145578 A JP2018145578 A JP 2018145578A JP 2018145578 A JP2018145578 A JP 2018145578A JP 2018196385 A5 JP2018196385 A5 JP 2018196385A5
Authority
JP
Japan
Prior art keywords
birc5
normalized
ube2c
breast cancer
level
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018145578A
Other languages
English (en)
Japanese (ja)
Other versions
JP7042717B2 (ja
JP2018196385A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2018196385A publication Critical patent/JP2018196385A/ja
Publication of JP2018196385A5 publication Critical patent/JP2018196385A5/ja
Application granted granted Critical
Publication of JP7042717B2 publication Critical patent/JP7042717B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018145578A 2009-11-23 2018-08-02 癌の臨床転帰を予測する方法 Active JP7042717B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26376309P 2009-11-23 2009-11-23
US61/263,763 2009-11-23

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2016129697A Division JP2016214245A (ja) 2009-11-23 2016-06-30 癌の臨床転帰を予測する方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020218527A Division JP2021058207A (ja) 2009-11-23 2020-12-28 癌の臨床転帰を予測する方法

Publications (3)

Publication Number Publication Date
JP2018196385A JP2018196385A (ja) 2018-12-13
JP2018196385A5 true JP2018196385A5 (enExample) 2019-02-28
JP7042717B2 JP7042717B2 (ja) 2022-03-28

Family

ID=44060376

Family Applications (7)

Application Number Title Priority Date Filing Date
JP2012540103A Active JP5964752B2 (ja) 2009-11-23 2010-11-19 癌の臨床転帰を予測する方法
JP2016129697A Pending JP2016214245A (ja) 2009-11-23 2016-06-30 癌の臨床転帰を予測する方法
JP2018145578A Active JP7042717B2 (ja) 2009-11-23 2018-08-02 癌の臨床転帰を予測する方法
JP2020218527A Pending JP2021058207A (ja) 2009-11-23 2020-12-28 癌の臨床転帰を予測する方法
JP2022123265A Pending JP2022166064A (ja) 2009-11-23 2022-08-02 癌の臨床転帰を予測する方法
JP2022129605A Pending JP2022169647A (ja) 2009-11-23 2022-08-16 癌の臨床転帰を予測する方法
JP2023213416A Active JP7823012B2 (ja) 2009-11-23 2023-12-18 癌の臨床転帰を予測する方法

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2012540103A Active JP5964752B2 (ja) 2009-11-23 2010-11-19 癌の臨床転帰を予測する方法
JP2016129697A Pending JP2016214245A (ja) 2009-11-23 2016-06-30 癌の臨床転帰を予測する方法

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2020218527A Pending JP2021058207A (ja) 2009-11-23 2020-12-28 癌の臨床転帰を予測する方法
JP2022123265A Pending JP2022166064A (ja) 2009-11-23 2022-08-02 癌の臨床転帰を予測する方法
JP2022129605A Pending JP2022169647A (ja) 2009-11-23 2022-08-16 癌の臨床転帰を予測する方法
JP2023213416A Active JP7823012B2 (ja) 2009-11-23 2023-12-18 癌の臨床転帰を予測する方法

Country Status (13)

Country Link
US (4) US20110123990A1 (enExample)
EP (4) EP3556867A1 (enExample)
JP (7) JP5964752B2 (enExample)
AU (1) AU2010321829B2 (enExample)
CA (2) CA3043089A1 (enExample)
DK (1) DK2504451T3 (enExample)
ES (1) ES2735993T3 (enExample)
HU (1) HUE044374T2 (enExample)
IL (5) IL219051A (enExample)
MX (3) MX363817B (enExample)
NZ (1) NZ599194A (enExample)
PL (1) PL2504451T3 (enExample)
WO (1) WO2011063274A2 (enExample)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040231909A1 (en) 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
EP1737980A2 (en) 2004-04-09 2007-01-03 Fondazione IRCCS Istituto Nazionale dei Tumori Gene expression markers for predicting response to chemotherapy
CA2585571C (en) * 2004-11-05 2020-01-21 Genomic Health, Inc. Predicting response to chemotherapy using gene expression markers
US7888019B2 (en) 2006-03-31 2011-02-15 Genomic Health, Inc. Genes involved estrogen metabolism
MX2010014280A (es) * 2008-06-26 2011-05-23 Dana Farber Cancer Inst Inc Distintivos y determinantes asociados con metástasis y método para utilizarlos.
US20120041274A1 (en) 2010-01-07 2012-02-16 Myriad Genetics, Incorporated Cancer biomarkers
DK177532B1 (en) 2009-09-17 2013-09-08 Bio Bedst Aps Medical use of sPLA2 hydrolysable liposomes
JP5964752B2 (ja) * 2009-11-23 2016-08-03 ジェノミック ヘルス， インコーポレイテッド 癌の臨床転帰を予測する方法
MX375138B (es) 2010-01-11 2025-03-06 Genomic Health Inc Método para usar expresión génica para determinar la probabilidad de un desenlace clínico de cáncer renal.
GB201009798D0 (en) 2010-06-11 2010-07-21 Immunovia Ab Method,array and use thereof
US20120053253A1 (en) 2010-07-07 2012-03-01 Myriad Genetics, Incorporated Gene signatures for cancer prognosis
EP2913405B1 (en) 2010-07-27 2016-11-09 Genomic Health, Inc. Method for using gene expression to determine prognosis of prostate cancer
EP2611941A4 (en) 2010-08-30 2014-01-22 Myriad Genetics Inc GENESIS OF CANCER DIAGNOSIS AND PROGNOSIS
US8361720B2 (en) 2010-11-15 2013-01-29 Exact Sciences Corporation Real time cleavage assay
US8916344B2 (en) 2010-11-15 2014-12-23 Exact Sciences Corporation Methylation assay
CA2831074A1 (en) * 2011-03-26 2012-10-04 Oregon Health And Science University Gene expression predictors of cancer prognosis
CA2840472A1 (en) * 2011-06-22 2012-12-27 Oncocyte Corporation Methods and compositions for the treatment and diagnosis of bladder cancer
WO2013006495A2 (en) * 2011-07-01 2013-01-10 Dana-Farber Cancer Institute, Inc. Methods of predicting prognosis in cancer
AU2012281152B2 (en) * 2011-07-13 2017-09-07 The Multiple Myeloma Research Foundation, Inc. Methods for data collection and distribution
EP2744917A4 (en) * 2011-08-16 2015-10-14 Oncocyte Corp METHOD AND COMPOSITIONS FOR THE TREATMENT AND DIAGNOSIS OF BREAST CANCER
WO2013070521A1 (en) * 2011-11-08 2013-05-16 Genomic Health, Inc. Method of predicting breast cancer prognosis
JP5805518B2 (ja) * 2011-12-21 2015-11-04 株式会社島津製作所 マルチプレックス大腸がんマーカーパネル
US8725426B2 (en) 2012-01-31 2014-05-13 Genomic Health, Inc. Gene expression profile algorithm and test for determining prognosis of prostate cancer
GB201206323D0 (en) * 2012-04-10 2012-05-23 Immunovia Ab Methods and arrays for use in the same
EP2839034A4 (en) * 2012-04-20 2016-01-06 Sloan Kettering Inst Cancer ASSOCIATED GENE EXPRESSION PROFILES ASSOCIATED WITH METASTASISING BREAST CANCER
WO2014055398A1 (en) 2012-10-05 2014-04-10 Siemens Healthcare Diagnostics Inc. Method for detecting an increased risk or incidence of colorectal cancer
ES2938766T3 (es) 2012-11-16 2023-04-14 Myriad Genetics Inc Firmas génicas para el pronóstico de cáncer
KR101672531B1 (ko) * 2013-04-18 2016-11-17 주식회사 젠큐릭스 조기 유방암 예후 예측 진단용 유전자 마커 및 이의 용도
US10181008B2 (en) * 2013-05-30 2019-01-15 Genomic Health, Inc. Gene expression profile algorithm for calculating a recurrence score for a patient with kidney cancer
WO2014195032A1 (en) * 2013-06-07 2014-12-11 Medical Prognosis Institute A/S Methods and devices for predicting treatment efficacy of fulvestrant in cancer patients
WO2015138769A1 (en) * 2014-03-12 2015-09-17 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for assessing patients with non-small cell lung cancer
EP3143160B1 (en) 2014-05-13 2019-11-06 Myriad Genetics, Inc. Gene signatures for cancer prognosis
US10184154B2 (en) 2014-09-26 2019-01-22 Mayo Foundation For Medical Education And Research Detecting cholangiocarcinoma
US10570457B2 (en) 2014-09-26 2020-02-25 Medical Prognosis Institute A/S Methods for predicting drug responsiveness
WO2016092299A1 (en) * 2014-12-09 2016-06-16 Medical Research Council Methods and kits for predicting the response to therapy of cancer
EP3274440B1 (en) 2015-03-27 2026-03-04 Exact Sciences Corporation Detecting esophageal disorders
KR102811214B1 (ko) 2015-10-30 2025-05-27 이그잭트 사이언시즈 코포레이션 복합 증폭 검출 분석 및 혈장으로부터 dna의 분리 및 검출 방법
EP3389481A4 (en) 2015-12-18 2019-05-22 Clear Gene, Inc. PROCESSES, COMPOSITIONS, KITS AND DEVICES FOR FAST LANALYSIS OF BIOLOGICAL MARKERS
SG11201901466PA (en) * 2016-09-07 2019-03-28 Agency Science Tech & Res A method of identifying risk of cancer and therapeutic options
US9725769B1 (en) 2016-10-07 2017-08-08 Oncology Venture ApS Methods for predicting drug responsiveness in cancer patients
AU2017258901A1 (en) 2016-12-30 2018-07-19 Allarity Therapeutics Europe ApS Methods for predicting drug responsiveness in cancer patients
JP7289264B2 (ja) 2017-01-27 2023-06-09 エグザクト サイエンシーズ コーポレーション メチル化ｄｎａの分析による結腸腫瘍の検出
WO2018212192A1 (ja) * 2017-05-18 2018-11-22 京都府公立大学法人 癌の予後及び／又は転移可能性を評価する方法及びマーカー
US12275994B2 (en) * 2017-06-22 2025-04-15 Clear Gene, Inc. Methods and compositions for the analysis of cancer biomarkers
CA3036161C (en) 2017-11-13 2023-03-28 The Multiple Myeloma Research Foundation, Inc. Integrated, molecular, omics, immunotherapy, metabolic, epigenetic, and clinical database
US10648025B2 (en) 2017-12-13 2020-05-12 Exact Sciences Development Company, Llc Multiplex amplification detection assay II
US11549152B2 (en) * 2018-03-08 2023-01-10 University Of Notre Dame Du Lac Products for assessing colorectal cancer molecular subtype and risk of recurrence and for determining and administering treatment protocols based thereon
JP7199045B2 (ja) * 2018-04-13 2023-01-05 国立大学法人大阪大学 乳癌の予後に関する情報の取得方法、乳癌の予後の判定装置及びコンピュータプログラム
US20220120753A1 (en) * 2018-09-21 2022-04-21 The University Of Tokyo Method for determining prognosis of cancer
JP2019032334A (ja) * 2018-10-03 2019-02-28 イムノヴィア・アクチエボラーグ 乳癌関連の疾患状態を決定する方法およびこの方法における使用のためのアレイ
KR102216645B1 (ko) * 2018-10-29 2021-02-17 사회복지법인 삼성생명공익재단 폐암의 분자 아형 결정을 위한 바이오마커 패널 및 이의 용도
MX2021006560A (es) * 2018-12-08 2021-11-17 Pfs Genomics Inc Perfilado transcriptómico para prognosis de cáncer de mama.
SG11202111940XA (en) * 2019-05-03 2021-12-30 Dcgen Co Ltd Method of predicting cancer prognosis and composition for same
CN111235270B (zh) * 2019-08-29 2022-04-29 北京臻知医学科技有限责任公司 一种基于高通量测序法的肿瘤抗原表达检测引物及试剂盒
US12165747B2 (en) * 2020-01-23 2024-12-10 The Broad Institute, Inc. Molecular spatial mapping of metastatic tumor microenvironment
AU2022220330A1 (en) * 2021-02-12 2023-09-14 Mammogen, Inc. Biomarkers for the diagnosis of breast cancer
WO2022192128A2 (en) * 2021-03-08 2022-09-15 Castle Biosciences, Inc. Determining prognosis and treatment based on clinical-pathologic factors and continuous multigene-expression profile scores
CN117116345B (zh) * 2023-07-24 2025-09-16 中国人民解放军军事科学院军事医学研究院 一种基于基因调控网络构建患者生存网络的方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1410011T3 (da) 2001-06-18 2011-07-18 Netherlands Cancer Inst Diagnose og prognose for brystcancerpatienter
US7171311B2 (en) * 2001-06-18 2007-01-30 Rosetta Inpharmatics Llc Methods of assigning treatment to breast cancer patients
AU2002322280A1 (en) * 2001-06-21 2003-01-21 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
DK3115470T3 (en) * 2002-03-13 2018-11-05 Genomic Health Inc Gene Expression Profiling in Tumor Tissue Biopsies
US20040067234A1 (en) * 2002-07-11 2004-04-08 Paz Einat Isocitrate dehydrogenase and uses thereof
US20040231909A1 (en) * 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
ES2905579T3 (es) * 2003-07-10 2022-04-11 Genomic Health Inc Algoritmo del perfil de expresión y prueba para el pronóstico de la recaída del cáncer de mama
WO2005086891A2 (en) * 2004-03-05 2005-09-22 Rosetta Inpharmatics Llc Classification of breast cancer patients using a combination of clinical criteria and informative genesets
CA2582739A1 (en) * 2004-09-30 2006-04-13 Bayer Healthcare Ag Methods and kits for the prediction of therapeutic success and recurrence free survival in cancer therapy
JP2008534002A (ja) 2005-04-01 2008-08-28 エヌシィーシィー テクノロジー ベンチャーズ ピィーティーイー．リミテッド 乳癌の分類に関する材料および方法
WO2006133460A2 (en) 2005-06-09 2006-12-14 Yale University Methods for diagnosing and treating breast cancer based on a her/er ratio
US20070099209A1 (en) * 2005-06-13 2007-05-03 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
WO2006138275A2 (en) * 2005-06-13 2006-12-28 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
TWI304443B (en) * 2005-12-30 2008-12-21 Nat Health Research Institutes Alpha-enolase specific antibody and method of use
US7888019B2 (en) * 2006-03-31 2011-02-15 Genomic Health, Inc. Genes involved estrogen metabolism
US20100234292A1 (en) * 2007-04-16 2010-09-16 Ipsogen Methods of assessing a propensity of clinical outcome for a female mammal suffering from breast cancer
WO2008150512A2 (en) * 2007-06-04 2008-12-11 University Of Louisville Research Foundation, Inc. Methods for identifying an increased likelihood of recurrence of breast cancer
WO2009095319A1 (en) * 2008-01-28 2009-08-06 Siemens Healthcare Diagnostics Gmbh Cancer prognosis by majority voting
WO2009132928A2 (en) * 2008-05-02 2009-11-05 Siemens Healthcare Diagnostics Gmbh Molecular markers for cancer prognosis
CA2723972A1 (en) * 2008-05-12 2009-11-19 Genomic Health Inc. Tests to predict responsiveness of cancer patients to chemotherapy treatment options
JP5964752B2 (ja) * 2009-11-23 2016-08-03 ジェノミック ヘルス， インコーポレイテッド 癌の臨床転帰を予測する方法

Similar Documents

Publication Publication Date Title
JP2018196385A5 (enExample)
JP2016214245A5 (enExample)
Huang et al. Exosomal miR-1290 and miR-375 as prognostic markers in castration-resistant prostate cancer
JP2021177761A5 (enExample)
JP2020188787A (ja) 膵臓がんの検出キット又はデバイス及び検出方法
JP2010538609A5 (enExample)
JP2016174600A5 (enExample)
CN106148529B (zh) 与胃癌相关的LncRNA标记物及其专用检测引物、检测方法、试剂盒与应用
CN105603101B (zh) 检测8个miRNA表达量的系统在制备诊断或辅助诊断肝细胞癌产品中的应用
Marín-Aguilera et al. Molecular profiling of peripheral blood is associated with circulating tumor cells content and poor survival in metastatic castration-resistant prostate cancer
JP2016521979A5 (enExample)
Wan et al. Diagnostic significance of circulating long noncoding RNA PCAT6 in patients with non-small cell lung cancer
JP6611411B2 (ja) 膵臓がんの検出キット及び検出方法
Zhao et al. Diagnostic value of NKG2D promoter methylation in hepatitis B virus-associated hepatocellular carcinoma
Zhu et al. Long intergenic non-protein coding RNA 1006 used as a potential novel biomarker of gastric cancer
CN111172285A (zh) 用于胰腺癌早期诊断和/或预后监测的miRNA组及其应用
CN109477147A (zh) 用于皮肤癌分期和治疗的方法和材料
WO2020032228A1 (ja) 前立腺がんの検出のためのキット、デバイス及び方法
Lin et al. Down-regulation of tissue microRNA-126 was associated with poor prognosis in patients with cutaneous melanoma
Jani et al. Examining trends in kidney cancer mortality by gender and race in the United States: A 20-year analysis
CN107858424B (zh) miRNA-4731-3p作为原发性肺癌诊断标志物的应用
WO2020135422A1 (zh) 健康风险评估方法
CN116479123A (zh) m7G相关lncRNA作为生物标志物在肝癌预后或治疗反应预测中的应用及产品和系统
Pycha et al. Evaluation of the M371-test under real-life conditions for diagnosis and follow up of testicular germ cell tumors
RU2663078C1 (ru) Способ прогнозирования риска развития послеоперационных сердечно-сосудистых осложнений лапароскопических операций при метастатическом раке толстой кишки